Search
Brexpiprazole
go.drugbank.com/drugs/DB09128ApprovedInvestigationalIt also displays stronger antagonism at the 5-HT1A and 5-HT2A receptors.[A182186, A38385, A259661] Brexpiprazole was first approved by the FDA on July 10, 2015. … Brexpiprazole is an atypical antipsychotic and a novel D2 dopamine and serotonin 1A partial agonist called serotonin-dopamine activity modulator (SDAM).
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: Rexulti 1mg film-coated tablets, Rexulti 2mg film-coated tabletsPlerixafor
go.drugbank.com/drugs/DB06809ApprovedInvestigational[A7115] Plerixafor has orphan drug status in the United States and European Union and was approved by the US Food and Drug Administration on December 15, 2008.[A7117,L45678] … These stem cells are then collected and used in autologous stem cell transplantation to replace blood-forming cells destroyed by chemotherapy.
Categories: Antineoplastic and Immunomodulating AgentsProducts: Mozobil Solution for Injection 20mg/ml, PLERISTEM (Plerixafor 20mg/mL Solution for Injection)Apremilast
go.drugbank.com/drugs/DB05676ApprovedInvestigationalIt belongs to the same drug class as [Roflumilast] and [Crisaborole].[A181244,L7495] Initially approved in 2014, it is marketed by Celgene. … [L7501] In July 2019, apremilast was granted a new FDA approval for the treatment of oral ulcers associated with Behcet's disease, an autoimmune condition that causes recurrent skin, blood vessel, and
Categories: Antineoplastic and Immunomodulating AgentsSynonyms: N-{2-[(1S)-1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamideFondaparinux
go.drugbank.com/drugs/DB00569ApprovedInvestigationalOnce bound to heparin or HS, the anticoagulant activity of ATIII is potentiated by 1000-fold. Fondaparinux potentiates the neutralizing action of ATIII on activated Factor X 300-fold. … angina (UA) and non-ST segment elevation myocardial infarction (NSTEMI); and in the management of ST segment elevation myocardial infarction (STEMI).
Categories: Blood and Blood Forming OrgansProducts: ARIXTRA ® 10MG /0.8 ML, ARIXTRA 2.5MG/0.5ML SOLUTION FOR INJECTIONAntihemophilic factor human
go.drugbank.com/drugs/DB13192ApprovedInvestigationalFactor VIII, but does not contain the B-domain, which has no known biological function and [DB11607], which is a fully recombinant factor VIII-Fc fusion protein which has an extended half-life compared … Other drug products with similar structure and function to Antihemophilic factor human include [DB13999], which is produced by recombinant DNA technology and is identical in sequence to endogenously produced
Mixtures: Haemate P Powder and solvent for solution for injection or infusion, Wilate 500, 500 IU VWF/500 IU FVIII, Powder and Solvent for Solution for InjectionCategories: Blood and Blood Forming Organs, Amino Acids, Peptides, and ProteinsMidostaurin
go.drugbank.com/drugs/DB06595ApprovedInvestigationalIt was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents. … It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors [A19108].
Categories: Antineoplastic and Immunomodulating AgentsSynonyms: 4'-N-benzoylstaurosporineCetylpyridinium
go.drugbank.com/drugs/DB11073ApprovedInvestigationalIn these products, it generally mediates an antiseptic activity and protective action against dental plaque and reducing gingivitis. … Its salt form, cetylpyridinium chloride, is typically found as an active ingredient in mouthwashes, toothpastes, lozenges, throat sprays, breath sprays, and nasal sprays.
Mixtures: rrub Rinse Free Hand Wash-non Alcohol version, BUCOSEPTOL NCategories: Alimentary Tract and Metabolism, Mouthwashes and GarglesZidovudine
go.drugbank.com/drugs/DB00495ApprovedInvestigationalA dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. … Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. [PubChem]
Mixtures: N/A, LAVUZID® NCategories: zidovudine and lamivudine, zidovudine, lamivudine and abacavirDoxazosin
go.drugbank.com/drugs/DB00590ApprovedInvestigational[A180649] It is marketed by Pfizer and was initially approved by the FDA in 1990.[L7285] … Doxazosin is an alpha-1 antagonist used for the treatment of benign prostatic hypertrophy (BPH) symptoms and hypertension.
Mixtures: Cardura-1,2,and 4, Cardura-1,2,and 4Categories: doxazosin and finasteride, Genito Urinary System and Sex HormonesExemestane
go.drugbank.com/drugs/DB00990ApprovedInvestigationalExemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal … It irreversibly binds to the active site of the enzyme resulting in permanent inhibition.
Categories: Antineoplastic and Immunomodulating Agents, Hormone Antagonists and Related AgentsProducts: TABLET 25MG, EXESTAN 25MG